IMW 2019 | DNA methyltransferase inhibitors: daratumumab enhancement for MM

Priya Choudhry

Priya Choudhry, PhD, from the University of California, San Francisco, CA, discusses how the use of DNA methyltransferase inhibitors upregulate CD38 expression and enhance daratumumab efficacy at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  
Similar topics
Related videos
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
An exciting era for CAR T-cell therapy
Mohamad Mohty
Multiple Myeloma
Antibodies, Daratumumab
IMW 2019
Interview
More from Priya Choudhry
Daratumumab enhancement for MM: the clinical impact
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals